Seres Therapeutics to Present at Two Upcoming June Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced it will present at each of the following upcoming healthcare conferences:

• Jefferies 2018 Global Healthcare Conference: a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New York, NY.
• Goldman Sachs 39th Annual Global Healthcare Conference: a corporate overview will be presented on Wednesday, June 13 at 9:20 a.m. PT in Palos Verdes, CA.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180601005213/en/

IR or PR:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications
[email protected]

Source: Seres Therapeutics, Inc.

You May Also Be Interested In

• Seres Therapeutics (MCRB) files $300M mixed shelf
• Jefferies Upgrades Minerva Neurosciences (NERV) to Buy
• Cryptocurrency Investments That Still Have Room, Starting With $BULLSKI